Each 5ml (one teaspoonful) of the reconstituted suspension contains Cefuroxime Axetil USP equivalent to Cefuroxime 152mg.

Cefuroxime Axetil is an oral prodrug of the bactericidal cephalosporin antibiotic Cefuroxime, which is resistant to most beta-lactamases and its active against a wide range of gram-positive and gram-negative organisms.

Cefuroxime Axetil owes its in vivo bactericidal activity to the parent compound. Cefuroxime is a well-characterized and effective antibacterial agent which has a broad-spectrum bactericidal activity against a wide range of common pathogens, including beta-lactamase-producing stains. Cefuroxime has good stability to bacterial beta-lactamase and consequently, is active against many ampicillin-resistant and amoxicillin-resistant strains. The bactericidal action of Cefuroxime results from inhibition of cell-wall synthesis by binding to essential target proteins.

After oral administration, Cefuroxime Axetil is absorbed form the gastrointestinal tract and rapidly hydrolyzed in the intestinal mucosa and blood to release Cefuroxime into the circulation. Peak serum Cefuroxime levels occur approximately two to three hours after oral dosing.

The serum half-life is about 1.2 hours. Approximately 50% serum Cefuroxime is protein bound.

Cefuroxime is not metabolised and is excreted by glomerular and tubular secretion.

Cefuroxime Axetil for oral suspension indicated for the treatment of infections caused by sensitive bacteria. Cefuroxime - Axetil is available in dry sryup30ml/60ml and 70ml and 100ml HPDE bottle containing powder.